Tibra Equities Europe’s Pacira BioSciences PCRX Stock Holding History

Tibra Equities Europe’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-15,200	Closed	-$579K	–	393
2019 Q1	$579K	Buy	+15,200	New	+$593K	0.06%	249

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tibra Equities Europe's PCRX Position: Q2 2019 in Review

Tibra Equities Europe sold out of Pacira BioSciences (PCRX) in Q2 2019, closing a stake of 15,200 shares — an estimated $579K sold.

Tibra Equities Europe first reported a position in PCRX in Q1 2019 and held it in 1 quarter. The position peaked at $579K in Q1 2019. 218 funds tracked by Wall St. Rank hold PCRX as of Q2 2019.

Tibra Equities Europe reported no remaining Pacira BioSciences position as of Q2 2019 after selling out during the quarter.
Tibra Equities Europe sold 15,200 Pacira BioSciences shares in Q2 2019, an estimated $579K.
Tibra Equities Europe first reported a position in Pacira BioSciences in Q1 2019 and held it in 1 quarter.
Tibra Equities Europe's Pacira BioSciences position peaked at $579K in Q1 2019.
218 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.